India's Biocon sees oral insulin partner by March
(For other news from the Reuters India Investment Summit, click here)
BANGALORE Nov 23 (Reuters) - Biocon Ltd, India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive said on Wednesday .
"We are in advanced discussions with potential partners," Biocon's Managing Director Kiran Mazumdar-Shaw told the Reuters India Investment Summit in Bangalore.
In January, Biocon had said it was looking for a partner after its oral insulin, IN-105, failed to meet the main goal of an Indian late-stage trial in patients with type-2 diabetes.
Mazumdar-Shaw, however, declined to name any potential partners.
She also said the planned IPO of its contract research organisation, Syngene, was on track.
(For summit blog: blogs.reuters.com/summits/)
(For more on the Reuters India Investment Summit, see ) (Reporting by Anand Basu, Jochelle Mendonca and Aftab Ahmed in Bangalore. Editing by Sriraj Kalluvila, Saumyadeb Chakrabarty)
Trending On Reuters
Prime Minister Narendra Modi has asked for a drastic cutback of an ambitious health care plan after cost estimates came in at $18.5 billion over five years, several government sources said, delaying a promise made in his election manifesto. Full Article